dc.contributor.author | de Winter, Jobst | |
dc.contributor.author | Murphy, Sabina A. | |
dc.contributor.author | McCabe, Carolyn H. | |
dc.contributor.author | Gibson, C. Michael | |
dc.contributor.author | Zorkun, Cafer | |
dc.contributor.author | Molhoek, Peter | |
dc.contributor.author | Zmudka, Krzysztof | |
dc.contributor.author | Greenberg, Mark | |
dc.contributor.author | Mueller, Hiltrud | |
dc.contributor.author | Wesdorp, Jan | |
dc.contributor.author | Louwerenburg, Hans | |
dc.contributor.author | Niederman, Alan | |
dc.contributor.author | Westenburg, Jaap | |
dc.contributor.author | Bikkina, Mahesh | |
dc.contributor.author | Batty, John | |
dc.date.accessioned | 2022-02-18T11:21:38Z | |
dc.date.available | 2022-02-18T11:21:38Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | Gibson C. M. , Zorkun C., Molhoek P., Zmudka K., Greenberg M., Mueller H., Wesdorp J., Louwerenburg H., Niederman A., Westenburg J., et al., "Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial", JOURNAL OF THROMBOSIS AND THROMBOLYSIS, cilt.22, sa.1, ss.13-21, 2006 | |
dc.identifier.issn | 0929-5305 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_ee07889f-4208-41d3-b39d-bf580c301fb8 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/181019 | |
dc.identifier.uri | https://doi.org/10.1007/s11239-006-8080-1 | |
dc.description.abstract | Background: Currently available fibrinolytic agents are limited by their ability to restore normal blood flow in only half of patients, the risk of reocclusion, and the risk of intracranial hemorrhage. The genetically engineered agent BB-10153 is activated by thrombin, not plasminogen activator enzymes, which limits its activity to the site of thrombus which may in turn reduce the risk of systemic bleeding. BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2]. | |
dc.language.iso | eng | |
dc.subject | Hematology | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Hematoloji | |
dc.subject | Kardiyoloji | |
dc.subject | Cardiology and Cardiovascular Medicine | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Health Sciences | |
dc.subject | CARDIAC ve CARDIOVASCULAR SİSTEMLER | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | HEMATOLOJİ | |
dc.subject | PERİFERAL VASKÜLER HASTALIĞI | |
dc.subject | Tıp | |
dc.title | Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF THROMBOSIS AND THROMBOLYSIS | |
dc.contributor.department | , , | |
dc.identifier.volume | 22 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 13 | |
dc.identifier.endpage | 21 | |
dc.contributor.firstauthorID | 3374105 | |